Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Advisory Committees

Waivers for Conflicts of Interest for the October 27, 2009 Meeting of the Anti-Infective Drugs Advisory Committee

The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.

Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007.  This provision was repealed, effective October 1, 2007, by the FDA.

Paul Ambrose, Pharm.D.

• 18 U.S.C. 208 waiver (pdf)

• Disclosure Document (pdf)

Page Last Updated: 12/09/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.